351 related articles for article (PubMed ID: 27405796)
1. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
Tiwari SR; Mishra P; Abraham J
Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
[TBL] [Abstract][Full Text] [Related]
2. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
Zhang X; Munster PN
Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
[TBL] [Abstract][Full Text] [Related]
3. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
Iwata H; Masuda N; Kim SB; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; Lu YS; Xu B; Yap YS; Bustam A; Yao B; Zhang B; Bryce R; Chan A
Future Oncol; 2019 Jul; 15(21):2489-2501. PubMed ID: 31140297
[No Abstract] [Full Text] [Related]
4. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
[TBL] [Abstract][Full Text] [Related]
5. Neratinib (HKI-272) in the treatment of breast cancer.
López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations.
Kourie HR; Chaix M; Gombos A; Aftimos P; Awada A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):947-57. PubMed ID: 27284682
[TBL] [Abstract][Full Text] [Related]
7. Neratinib (Nerlynx) for HER2-positive breast cancer.
Med Lett Drugs Ther; 2018 Jan; 60(1539):23. PubMed ID: 29364199
[No Abstract] [Full Text] [Related]
8. Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.
Jerez Y; Herrero B; Arregui M; Morón B; Martín M; Echavarría I
Future Oncol; 2020 Jun; 16(17):1165-1177. PubMed ID: 32458702
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
10. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
11. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis.
Nasrazadani A; Brufsky A
Future Oncol; 2020 Mar; 16(7):247-254. PubMed ID: 32057254
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
13. Neratinib for the treatment of HER2-positive early stage breast cancer.
Echavarria I; López-Tarruella S; Márquez-Rodas I; Jerez Y; Martin M
Expert Rev Anticancer Ther; 2017 Aug; 17(8):669-679. PubMed ID: 28649882
[TBL] [Abstract][Full Text] [Related]
14. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
Ben-Baruch NE; Bose R; Kavuri SM; Ma CX; Ellis MJ
J Natl Compr Canc Netw; 2015 Sep; 13(9):1061-4. PubMed ID: 26358790
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
[TBL] [Abstract][Full Text] [Related]
16. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman RA; Gelman RS; Wefel JS; Melisko ME; Hess KR; Connolly RM; Van Poznak CH; Niravath PA; Puhalla SL; Ibrahim N; Blackwell KL; Moy B; Herold C; Liu MC; Lowe A; Agar NY; Ryabin N; Farooq S; Lawler E; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU
J Clin Oncol; 2016 Mar; 34(9):945-52. PubMed ID: 26834058
[TBL] [Abstract][Full Text] [Related]
17. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
[TBL] [Abstract][Full Text] [Related]
18. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
19. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer.
Zhao M; Scott S; Evans KW; Yuca E; Saridogan T; Zheng X; Wang H; Korkut A; Cruz Pico CX; Demirhan M; Kirby B; Kopetz S; Diala I; Lalani AS; Piha-Paul S; Meric-Bernstam F
Clin Cancer Res; 2021 Mar; 27(6):1681-1694. PubMed ID: 33414137
[TBL] [Abstract][Full Text] [Related]
20. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
Dhillon S
Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
